High-throughput phenotypic screening of Medicines for Malaria Venture's Hit Generation Library 1 identifies new nematocidal chemotypes.

Aya C Taki, Joseph J Byrne, Bill C H Chang, Benoît Laleu, Timothy N C Wells, Abdul Jabbar, Robin B Gasser

Abstract read

In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aya C TakiDepartment of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria 3010, Australia.

Joseph J ByrneDepartment of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria 3010, Australia.

Bill C H ChangDepartment of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria 3010, Australia.

Benoît LaleuMedicines for Malaria Venture (MMV), 1215, Geneva, Switzerland.

Timothy N C WellsMedicines for Malaria Venture (MMV), 1215, Geneva, Switzerland.

Abdul JabbarDepartment of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria 3010, Australia.

Robin B GasserDepartment of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Science, The University of Melbourne, Parkville, Victoria 3010, Australia. Electronic address: robinbg@unimelb.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parasitic helminths impose substantial health and economic burdens on humans and livestock, and widespread resistance to existing anthelmintic classes underscores the urgent need for new chemotypes with distinct mechanisms of action as part of integrated parasite control strategies. Here, we performed a large-scale phenotypic screen of the Medicines for Malaria Venture Hit Generation Library 1 (HGL1), testing 139,916 compounds (98.7% of the 141,786-compound library) against exsheathed third-stage larvae of Haemonchus contortus, with selective cross-species evaluation in Caenorhabditis elegans. Using infrared-based motility and developmental assays in 384-well format, the platform delivered excellent performance across > 360 plates (mean Z' = 0.799 ± 0.012; signal-to-background = 65.6 ± 9.8). We identified 272 primary hits (0.194%) and confirmed 110 active compounds with reproducible inhibition of larval motility and development. Of these, 39 exhibited IC

Indexed as

AnthelminticsAntinematodal AgentsHaemonchusHigh-Throughput Screening AssaysAnimalsCaenorhabditis elegansDrug DiscoveryDrug Evaluation, PreclinicalHumansInhibitory Concentration 50LarvaMalariaPhenotypeAnthelminticsAntinematodal AgentsCaenorhabditis elegansDrug resistanceEarly anthelmintic discoveryHaemonchus contortusHigh-throughput screeningMMV Hit Generation Library 1Nematocidal compoundsPhenotypic screening

Identifiers

PMID41865685

DOI10.1016/j.ijpddr.2026.100638

PMCPMC13019932

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.